Reports from the GRADE Study

517 About the Artist: Jose F. Caro, MD
B. Page

518 About the Editor: Camille E. Powe, MD: Advancing Research for Diabetes and Pregnancy
B. Page

Profiles in Progress

520 David M. Nathan: An Epic Investigator, An Epoch in Diabetes Care
D.J. Wexler

In This Issue

527 In This Issue of Diabetes Care
M. Bingham

Editor’s Note

529 A Special Thanks to the Reviewers of Diabetes Care

Review

531 Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity
N. Sattar, C. Presslie, M.K. Rutter, and D.K. McGuire

ADA Statement

544 Diabetes Management in Detention Facilities: A Statement of the American Diabetes Association

556 Individualizing Treatment of Type 2 Diabetes After Metformin: More Insights From GRADE
M.C. Riddle

562 Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial

571 Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
Differential Treatment Effects of Dual Therapy
M.R. Gramzinski, T. Killean, V.L. Arends, and J.S. Gonzales, for the GRADE Research Group

580 Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial

589 Mortality in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

594 Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

603 Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

610 Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

620 Does Emotional Distress Predict Worse Glycemic Control Over Time? Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

629 Emotional Distress Predicts Reduced Type 2 Diabetes Treatment Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

638 The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Commentary

646 Prompt Recognition of New-Onset Type 1 Diabetes Is Everyone’s Responsibility—Even on Weekends
L.M. Jacobsen

Original Research

649 Association of Diabetic Ketoacidosis in Childhood New-Onset Type 1 Diabetes With Day of Presentation in Germany

653 Efficacy and Safety of Glucagon-Like Peptide-1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy

660 Demographic, Clinical, Management, and Outcome Characteristics of 8,004 Young Children With Type 1 Diabetes
J.L. Sandy, S.R. Tittel, S. Rompicherla, B. Karges, S. James, N. Ricles, A.G. Zimmerman, E. Fröhlich-Reiterer, D.M. Moahs, S. Lanzinger, M.E. Craig, and O. Eberkocien, on behalf of the Australasian Diabetes Data Network (ADDN), the T1D Exchange Quality Improvement Collaborative (T1DX-QI), and the Prospective Diabetes Follow-Up Registry Initiative (DPV)
668 Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes

676 Longitudinal Changes in Sex Hormone Binding Globulin (SHBG) and Risk of Incident Diabetes: The Study of Women’s Health Across the Nation (SWAN)

683 A Real-World Prospective Study of the Effectiveness and Safety of Automated Insulin Delivery Compared With Other Modalities of Type 1 Diabetes Treatment During Ramadan Intermittent Fasting
M.E. Al-Sofiani, S. Alharthi, S. Albunyan, N. Alzaman, D.C. Klonoff, and A. Alguwaihes

692 Disparities in Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Prescription and Dispensing in the Israeli Population—A Retrospective Cohort Study

698 Epidemiology and Prognostic Implications of Coronary Artery Calcium in Asymptomatic Individuals With Prediabetes: A Multicohort Study

707 Improved Glycemic Outcomes With Diabetes Technology Use Independent of Socioeconomic Status in Youth With Type 1 Diabetes

712 Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study

720 Lifetime Duration of Breastfeeding and Cardiovascular Risk in Women With Type 2 Diabetes or a History of Gestational Diabetes: Findings From Two Large Prospective Cohorts

729 Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-Standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodense: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4
H.S. Boru, B. Àsbjörnsdóttir, L. Carstens, C. Leungesen, C. Mathieu, A. Philis-Tsimikas, and T. Battelino

739 Identifying Preferred Features of Weight Loss Programs for Adults With or at Risk of Type 2 Diabetes: A Discrete Choice Experiment With 3,960 Adults in the U.K.

747 Improved Satisfaction While Maintaining Safety and High Time in Range (TIR) With a Medtronic Investigational Enhanced Advanced Hybrid Closed-Loop (e-AHCL) System

756 Prevalence and Predictive Factors for Celiac Disease in Children With Type 1 Diabetes: Whom and When to Screen? A Nationwide Longitudinal Cohort Study of Swedish Children

e-Letters — Comments and Responses

e32 Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
Diabetes Care 2024;47:2004–2014
G. Maltese and A.J. Sinclair

e34 Comment on Umaphathysivam et al. Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium–Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction. Diabetes Care 2024;47:140–143
Y. Nakasone, K. Yamashita, and T. Azawa

e35 Comment on Umaphathysivam et al. Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium–Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction. Diabetes Care 2024;47:140–143
N. Foussard, A. Larroumet, M.-A. Barbet-Massin, L. Blanco, K. Mohammed, T. Couffinhal, S. Fawaz, Y. Pucheu, and V. Rigalleau

K. Kawada

M.-P. St-Onge, F.M. Zurakat, B. Laferrère, S. Jelic, and B. Aggarwal

Errata

American Diabetes Association Professional Practice Committee

A.M. Kanaya

Issues and Events

764 Issues and Events